Category A drugs refer to those drugs that are necessary for clinical treatment, widely used, have good therapeutic effects, and are less expensive than their counterparts, and the costs incurred for the use of these drugs are included in the scope of the basic medical insurance fund, and are paid for in accordance with the provisions of the basic medical insurance scheme. Class B drugs are drugs that can be used for clinical treatment, have good therapeutic effects, and are more expensive than Class A drugs in the same category.
In the medical insurance drug catalog, Class A catalog is a guarantee catalog, in which the drugs are 100% reimbursed. It is understood that all therapeutic drugs within the National Essential Drugs Catalog are included in the new version of the Drug Catalog Category A drugs.
And for the drugs in Category B catalog, each region has 15% adjustment right. Each region can set a certain individual out-of-pocket percentage for Class B drugs according to the fund's affordability, and then pay according to the provisions of basic medical insurance. In other words, Class B drugs are not necessarily reimbursed at 100 percent.
Expanded Information:
In 2017, the National Health Insurance Catalog Class A proprietary Chinese medicines*** counted 195 categories, involving 370 varieties. New medicare class A varieties by therapeutic areas, gynecological products are the most, accounting for 1/4 of all the shortlisted varieties; other respiratory system, orofacial, skeletal-muscular system, oncology system, pediatrics shortlisted varieties followed,
and in the traditionally strong cardio-cerebral and cerebral vascular system diseases, digestive field almost no new medicare class A varieties. According to the dosage form and route of administration, the new Class A varieties of traditional Chinese medicine, all oral dosage form, none of the traditional Chinese medicine injection or external dosage form.
The new health insurance category A varieties, there are a lot of multiple production of proprietary Chinese medicine products, such as the seven centi-san 60 companies produce, Xuanmai Ganjie particles 72 companies produce these varieties, even if the health insurance policy to get a breakthrough, due to the market competition pattern is not clear, which companies to get a substantial benefit, remains to be seen.
Exclusive or quasi-exclusive products, is the health insurance category B into a category A substantial real benefits of enterprises and products. New medical insurance category A varieties, 32 exclusive dosage form products (40 for the exclusive dosage form products, there are a number of exclusive dosage form is in the same, hanhong tablets, hanhong capsule, hanhong granules are produced by the same enterprise, counting a variety), 30 of these products are shortlisted in the evaluation of the scope of the large varieties of traditional Chinese medicine.
In addition, in the remaining multiple varieties, stomatitis clear particles only two production, the real quasi-exclusive products, one of the products shortlisted for the assessment of large varieties of traditional Chinese medicine; Shuanghuanglian tablets (capsules, granules, composites) of various dosage forms are multiple production, a composite, two oral liquid products shortlisted for the assessment of large varieties of traditional Chinese medicine; other multiple products, are not shortlisted for the assessment of large varieties of traditional Chinese medicine.
Baidu Encyclopedia - Medicare Category A
Baidu Encyclopedia - Medicare Category B